{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122297","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.752605+00:00","generated_at":"2026-05-30T04:44:09.042442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics reports Q3 2024 net loss $88.1M; RLY-2608 shows 9.2-month median PFS","bullets":["Net loss $88.1M ($0.63/share); revenue $0 vs $25.2M year ago (prior Genentech milestone).","Cash $839.6M at Sep 30, 2024; expected to fund operations into H2 2027.","RLY-2608 + fulvestrant interim data: 9.2-month median PFS, 33% ORR in heavily pre-treated PI3Kα-mutated breast cancer.","Plan to initiate Phase 3 pivotal trial of RLY-2608 + fulvestrant in 2L breast cancer in 2025.","Raised $230M in Sep 2024 follow-on; streamlined R&D with ~$50M annual savings, 15% workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122297","json":"https://secwatch.observer/filing/0000950170-24-122297.json","markdown":"https://secwatch.observer/filing/0000950170-24-122297.md","text":"https://secwatch.observer/filing/0000950170-24-122297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/0000950170-24-122297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024122297/rlay-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:44:09.042442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}